4 June 2018 in Molecular Neurobiology
23 May 2017 in Frontiers in Pharmacology
Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia. More recently, it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration. These changes and their possible association with CBD beneficial effects in psychiatric disorders are reviewed here.
17 May 2011 in British Journal of Pharmacology
BACKGROUND AND PURPOSE Epigenetic modifications are thought to play an important role in the neurobiology of depression. Antidepressant treatment induces histone acetylation in the hippocampus, which is associated with transcriptional activation, whereas stress increases DNA methylation, which is associated with transcriptional repression. Because the specific involvement of DNA methylation in the regulation of depressive‐like behaviours is not yet known, we have investigated the effects induced by systemic or intra‐hippocampal administration of inhibitors of DNA methyltransferase (DNMT) in rats submitted to a range of behavioural tests.EXPERIMENTAL APPROACH Rats received i.p. injections of 5‐aza‐2‐deoxycytidine (5‐azaD, 0.1–0.8 mg·kg−1), 5‐azacytidine (5‐azaC, 0.4–3.2 mg·kg−1), imipramine (15 mg·kg−1) or vehicle and were submitted to the forced swimming test (FST) or open field test (OFT). Other groups of rats received intra‐hippocampal injection of DNMT inhibitors.KEY RESULTS Systemic administration of DNMT inhibitors induced a dose‐dependent antidepressant‐like effect, which was followed by decreased DNA methylation and increased brain‐derived neurotrophic factor (BDNF) levels in the hippocampus. Hippocampal inhibition of DNA methylation induced similar behavioural effects. No treatment induced any locomotor effects in the OFT. Antidepressant‐like effects of 5‐azaD were confirmed in mice submitted to the FST or the tail suspension test.CONCLUSIONS AND IMPLICATIONS Systemic, as well as hippocampal, inhibition of DNA methylation induced antidepressant‐like effects. These effects could be associated with increased hippocampal expression of BDNF. Our data give further support to the hypothesis that DNA methylation is an important epigenetic mechanism involved in the development of depressive‐like behaviours.
1 August 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
1 July 2019 in Journal of Chemical Neuroanatomy
GSGabriela Pandini Silote
+1
1 August 2001 in Brain Research Bulletin
MSMaria Cristina Leite Silveira
Maria Cristina Leite Silveira
FGFrancisco Silveira Guimarães
Francisco Silveira Guimarães